7 Biotech Stocks With FDA Catalysts: Ranked by Risk-Reward

Update September 4, 2026: Ultragenyx (RARE) crashed 44% on September 3 to $14.85 after its Phase 3 Aspire trial of apazunersen (GTX-102) in Angelman syndrome failed (announced after the September 2 close) — see our breaking coverage. The September 19 UX111 PDUFA below is unchanged, but RARE now trades near a $1.5 billion market cap (down from $2.6 billion at publication), so the risk-reward framing must be read against that reset.

Update September 4, 2026: The IONS zilganersen PDUFA resolved early — approved September 3 as ZANVASTRO, the first Alexander disease treatment (see our approval coverage). IONS fell about 5.2% on the news (the approval was already priced in).

Biotech investing in H2 2026 is a target-rich environment. The FDA review calendar is packed with PDUFA dates through December, and if you know how to read a PDUFA date, you can position ahead of binary events that move stocks 20 to 50 percent in a single session.

Seven stocks with confirmed FDA catalysts in the next six months, ranked by risk-reward rather than market cap. Each pick has a specific PDUFA date, clinical trial data, and a number behind the thesis. Two of these are explicit avoid calls. If you want the broader Q3 FDA calendar, we track every date there.

Update September 3, 2026: The Sarepta (SRPT) contrarian pick below (entry #5) has played out. SRPT closed at $23.21 on September 2 (Polygon), up 48% from the $15.43 cited at publication, lifting the market cap to about $2.25 billion and the price-to-sales ratio to about 1.0x (from under 0.6x). The “market is pricing in failure” thesis has re-rated. See our Sarepta CEO coverage.

1. Cogent Biosciences (COGT) | $40.67 | Market Cap $6.9B | PDUFA Nov 30 and Dec 30

Cogent has two bezuclastinib PDUFA dates: November 30 for GIST in combination with sunitinib (Priority Review), and December 30 for non-advanced systemic mastocytosis as monotherapy. The SUMMIT trial hit its primary endpoint hard: total symptom score improved 43 percent on bezuclastinib versus 29 percent on placebo (p<0.001). Thirty-four percent of treated patients achieved a 50 percent or greater TSS reduction versus 18 percent on placebo (p=0.01). Biomarkers were even cleaner: 87.4 percent achieved a 50 percent or greater reduction in serum tryptase.

The comp is Blueprint Medicines, which got avapritinib approved for advanced systemic mastocytosis. Cogent is targeting non-advanced SM, a population roughly 5x larger than the advanced form, where no drug is specifically approved. Bezuclastinib also carries FDA Breakthrough Therapy designation for GIST, where it would be the first new therapy in over 20 years. Cogent ranks first because the clinical data hit p<0.001 on primary and secondary endpoints, and the market is under-pricing the NonAdvSM opportunity at $6.9B. We previously covered the GIST PDUFA in depth.

2. Ultragenyx (RARE) | $25.98 | Market Cap $2.6B | PDUFA Sept 19

UX111 is an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), a fatal neurodegenerative disease with a median life expectancy of 15 years and 3,000 to 5,000 patients in commercially accessible markets. The Transpher A study showed a 23.2-point treatment effect on Bayley-III cognitive scores versus natural history (p<0.0001) in children treated before age two. CSF heparan sulfate dropped a median 64 percent (p<0.001). These are not marginal numbers.

At $2.6B market cap, RARE is pricing in meaningful approval odds. The comp is Sarepta at $2.25B (re-rated from $1.68B at publication), which has $731M in quarterly revenue and multiple approved products. RARE has zero revenue and one BLA under review. But UX111 would be the first therapy for Sanfilippo, and orphan drug pricing in ultra-rare disease routinely exceeds $2M per patient. If approved, the stock re-rates to the upside. If the FDA issues a second CRL, the stock loses 40 percent. We covered the UX111 PDUFA analysis earlier.

3. Ionis Pharmaceuticals (IONS) | $55.30 | Market Cap $9.2B | PDUFA Sept 22

Zilganersen is an antisense oligonucleotide that reduces overproduction of glial fibrillary acidic protein, the underlying cause of Alexander disease. If approved, it would be the first disease-modifying therapy for a condition that affects roughly 1 in 1 to 3 million people worldwide. The FDA granted Priority Review with a September 22 PDUFA.

At $9.2B market cap, Ionis is the largest company on this list, and the stock will not double on a zilganersen approval. The drug targets an ultra-rare population. But Ionis has a deep pipeline of antisense assets, and each approval validates the platform. The comp is Alnylam at roughly $30B market cap with over $2B in annual revenue. Ionis at $9.2B with over $1B in annual revenue trades at roughly 7x revenue; Alnylam trades at 15x. The zilganersen PDUFA could start closing that valuation gap.

4. Savara (SVRA) | $5.33 | Market Cap $1.1B | PDUFA Nov 22 (extended)

MOLBREEVI (molgramostim) is an inhaled GM-CSF for autoimmune pulmonary alveolar proteinosis, a rare lung disease with no approved therapies in the US or Europe. The FDA extended the PDUFA from August 22 to November 22 after classifying Savara’s responses to information requests as a major amendment. The agency explicitly cited no safety, efficacy, or manufacturing concerns. This is an administrative extension, not a scientific red flag.

At $1.1B market cap, SVRA is a pure play on this single catalyst. First-in-class therapies for rare respiratory diseases have a strong approval track record when the FDA acknowledges the data package is sufficient. The risk is that the FDA convenes an advisory committee and raises questions about the clinical meaningfulness of pulmonary gas transfer improvements. The reward is that approval makes this a $2 to $3B company overnight. We track rare disease catalysts in our rare disease stocks roundup.

5. Sarepta Therapeutics (SRPT) | $23.21 | Market Cap $2.25B | Contrarian Pick (played out)

This is the stock the market hates. ELEVIDYS revenue declined to $102M in Q1 2026 from $110M in Q4 2025. The FDA forced a black box warning for acute liver injury. The company cut 36 percent of its workforce, roughly 500 employees, to save $400M annually. CEO Doug Ingram was replaced by Michael Severino effective July 28.

Here is the contrarian thesis. Sarepta generated $731M in total Q1 2026 revenue. The market cap is now $2.25B (re-rated from $1.68B at publication). That lifted the price-to-sales ratio to about 1.0x on an annualized basis, for a company with multiple approved Duchenne products and a gene therapy on the market. The restructuring is painful but necessary. Severino ran Vertex’s commercial engine and is a proven operator. If he stabilizes ELEVIDYS and advances the siRNA pipeline, this stock doubles from a low base. The Severino appointment was the first step.

The risk is real: ELEVIDYS could lose the non-ambulant population entirely if the enhanced immunosuppression protocol fails to satisfy the FDA. But at $2.25B, you are paying about 1.0x revenue for a franchise that generated nearly $3B annualized — the deep-value discount has narrowed. The market is pricing in failure. The market is wrong.

6. Replimune (REPL) | $12.86 | Market Cap ~$1.1B | PDUFA Aug 2 — APPROVED Aug 6

The FDA granted accelerated approval to Tudriqev (RP1) on August 6, 2026 — the company’s third BLA submission was the charm. The CTGTAC advisory committee voted 10-3 in favor on July 30 despite FDA briefing documents that called the IGNYTE study “not interpretable.” At the pre-AdComm trough, REPL fell to $5.35. After the 10-3 vote and subsequent approval, the stock surged to $12.86 on the August 6 close — a 140% gain in 8 days.

Reprimune is now a commercial-stage biotech with a first-in-class oncolytic virus immunotherapy. The confirmatory IGNYTE-3 Phase 3 trial is ongoing as a post-marketing requirement. Near-term catalysts: Q3 commercial launch metrics for Tudriqev and IGNYTE-3 enrollment updates. See our Tudriqev approval coverage.

7. GSK (GSK) | Avoid | PDUFA Nov 27 (neladalkib)

GSK completed its $10.6B acquisition of Nuvalent in July 2026. Zidesamtinib was approved by the FDA on July 22 for ROS1-positive NSCLC. The next catalyst is neladalkib, an ALK-selective inhibitor with a PDUFA of November 27 for TKI pre-treated ALK-positive NSCLC.

This is the avoid call. GSK is a mega-cap pharmaceutical company with a market cap north of $80B. Neladalkib’s peak sales estimate is $1 to $2B annually. Even at the high end, that is under 3 percent of GSK’s revenue base. The stock will not move on this PDUFA. If you want to play the oncology catalyst, GSK is the wrong vehicle. The oncology catalysts roundup has better pure plays. The drugs are good; the stock is uninvestable for catalyst-driven returns.

The Risks

Every stock on this list faces binary FDA risk. A complete response letter erases 30 to 50 percent of market cap in a single session. Cogent’s data hit p<0.001 on primary and secondary endpoints, but two PDUFA dates means two binary events. RARE is a gene therapy, and the FDA has been unpredictable on gene therapy approvals. SVRA’s three-month extension could signal deeper review concerns despite the agency’s reassurances. REPL has been approved — the binary risk has been resolved on the third attempt.

Top 3

1. COGT: p<0.001 data on primary and secondary endpoints, two shots on goal, underpriced NonAdvSM market. Buy for the catalyst and hold for the franchise.
2. RARE: first-in-disease gene therapy with p<0.0001 cognitive data. High risk, high reward at $2.6B.
3. SRPT: contrarian at publication — re-rated to about 1.0x revenue. The “market pricing in catastrophe” gap has closed.

Avoid GSK for catalyst investing. REPL has been approved and is now a commercial-stage story — the catalyst has played out. For more on how to approach biotech investing, start with our guide to investing in biotech.